This phase 3 randomized #ClinicalTrial demonstrates that #Penpulimab combined with #Chemotherapy significantly prolongs progression-free survival in recurrent or #Metastatic #NasopharyngealCarcinoma. @fudan-university.bsky.social

#STTT #OpenAccess: doi.org/10.1038/s413...

Findings from a phase II #ClinicalTrial reveal that perioperative #Penpulimab + #Anlotinib provides promising efficacy and a manageable safety profile for resectable #NSCLC, identifying a potent new combination therapy.
#STTT #OpenAccess: doi.org/10.1038/s413...

A multicenter, open-label, randomized, phase II trial evaluating the efficacy and safety of perioperative #Penpulimab plus #Anlotinib with or without #Neoadjuvant #Chemotherapy, promising efficacy and a manageable safety profile in patients with resectable #NSCLC
#OpenAccess: doi.org/10.1038/s413...

APOLLO Trial: OS Benefit with Anlotini Penpulimab in HCC APOLLO trial shows that penpulimab plus anlotinib significantly improves survival outcomes over sorafenib in unresectable HCC.

New Paper Alert: APOLLO Trial. Anlotinib Plus Penpulimab vs Sorafenib in First-Line Treatment of Unresectable Hepatocellular Carcinoma

oncodaily.com/opinion/apol...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #APOLLO #Anlotinib #Penpulimab #Sorafenib #HCC

Novel ICI–TKI combination outplays sorafenib in advanced HCC First-line treatment with anlotinib plus penpulimab significantly improves the outcomes of patients with unresectable hepatocellular carcinoma relative to sorafenib.

#MedNews - First-line treatment with #anlotinib plus #penpulimab significantly improves the outcomes of patients with unresectable hepatocellular carcinoma relative to #sorafenib.

Full story 👉 buff.ly/aA3W8IV

#OncSky #HCC

Akeso's Penpulimab Receives FDA Approval, Changing the Nasopharyngeal Carcinoma Landscape Akeso has achieved FDA approval for penpulimab, enhancing treatment options for nasopharyngeal carcinoma and competing robustly in the pharmaceutical market.

Akeso's Penpulimab Receives FDA Approval, Changing the Nasopharyngeal Carcinoma Landscape #USA #Las_Vegas #Akeso #Penpulimab #nasopharyngeal_carcinoma

FDA Approval of Penpulimab-kcqx for Nasopharyngeal Carcinoma by Oncology's Green Light Tune in to learn about penpulimab-kcqx, a significant advancement recently approved by the FDA for treating non-keratinizing metastatic nasopharyngeal carcinoma (NPC). This episode delves into the sci...

Tune in to the latest episode to learn about the FDA approval of penpulimab-kcqx for non-keratinizing metastatic nasopharyngeal carcinoma (NPC) #NPCCancer #Immunotherapy #Penpulimab #CancerTreatment #FDAApproval #Oncology #Podcast #FDA
creators.spotify.com/pod/show/onc...

Penpulimab: Uses in Cancer, Side Effects, Dosage, Expectations, and More - OncoDaily Learn about Penpulimab, its uses in cancer treatment, side effects, dosage, expectations, which is monoclonal antibody targets PD-1.

Penpulimab: Uses in Cancer, Side Effects, Dosage, Expectations, and More

oncodaily.com/drugs/penpul...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #Penpulimab #ImmunotherapyNasopharyngealCarcinoma #NPC #Immunotherapy

FDA Approves Penpulimab. A Powerful Step Forward in NPC Penpulimab receives FDA approval for recurrent or metastatic NPC. A new immunotherapy option for patients after platinum-based chemotherapy.

FDA Approves Penpulimab for Recurrent or Metastatic Non-Keratinizing Nasopharyngeal Carcinoma
@fda.gov

oncodaily.com/oncolibrary/...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #FDA #Penpulimab #NasopharyngealCarcinoma

Akeso's Penpulimab Achieves NMPA Approval for Nasopharyngeal Cancer Treatment Akeso's Penpulimab has been approved by NMPA for treating nasopharyngeal cancer, expanding patients' access to this innovative therapy.

Akeso's Penpulimab Achieves NMPA Approval for Nasopharyngeal Cancer Treatment #China #Hong_Kong #Akeso #Penpulimab #NPC